Voydeya
NDC Package 25682-049-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Voydeya is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Marketed by Alexion Pharmaceuticals Inc., this product is identified by NDC 25682-049 and is authorized under FDA application NDA218037.

Identification & Billing

NDC Package Code
25682-049-04
Package Description
4 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK (25682-049-42) * 21 TABLET, FILM COATED in 1 BLISTER PACK (25682-040-21) * 21 TABLET, FILM COATED in 1 BLISTER PACK (25682-043-21)
Product Code
25682-049
11-Digit Billing Format
25682004904
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Voydeya
Dosage Form
-
Usage Information
VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Regulatory & Marketing

Labeler Name
Alexion Pharmaceuticals Inc.
FDA Application #
NDA218037
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-29-2024
End Marketing Date
05-14-2026
Listing Expiration
05-14-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 25682-049-04 identifies a specific commercial package of 4 blister pack in 1 carton / 1 kit in 1 blister pack (25682-049-42) * 21 tablet, film coated in 1 blister pack (25682-040-21) * 21 tablet, film coated in 1 blister pack (25682-043-21) of Voydeya, labeled by Alexion Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Alexion Pharmaceuticals Inc. on March 29, 2024. The current certification is valid through May 14, 2026.

How is this Alexion Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 25682004904. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
25682-049-04
11-Digit CMS (5-4-2)
25682-0049-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.